A Phase 4 interventional study of Celecoxib and Placebo in Bowel Diseases, Inflammatory, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 26th largest by enrollment of the 327 interventional ones that give a count, is one of 5 that started in 2003, is one of 31 in phase 4, and was the 50th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.
Browse Inflammatory Bowel Diseases studies →103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Palisade Bio · Sites in United States, Canada, Czechia and 9 more countries
Ages 18–75
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of Michigan · Sites in United States
Ages 18+
Hope Biosciences Research Foundation · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
463 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 59 · Phase 2 83 · Phase 3 46 · Phase 4 31
First in 1995; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 408 is above the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.
Median enrollment 50 across the 327 interventional studies, 134 across the 132 observational. Of the 301 that completed or were terminated, 120 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
132 of 463 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
42 of the studies in Inflammatory Bowel Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT07769437University Hospitals Cleveland Medical CenterNon-nutritive Sweeteners in Inflammatory Bowel Disease | 2026-12 |
| NCT06065228Children's National Research InstituteTherapeutic Endpoint in Pediatric IBD Conditions | 2026-12 |
Add all 42 to your calendar (.ics) → With an account.
Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
Inclusion Criteria:
Inclusion criteria:
Exclusion Criteria:
Exclusion criteria:
Drug: Celecoxib
Other: Placebo
Drug: Ibuprofen plus Omeprazole
200 mg oral capsule twice daily for 2 weeks
Matched placebo for 2 weeks
Drug pages: Ibuprofen · Omeprazole
ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
Number of mucosal breaks in the small bowel for each subject
Time frame: Day 30
Adverse events
Time frame: Day 30
Laboratory tests
Time frame: Day 30
Vital signs
Time frame: Day 30
Correlation of number of mucosal breaks in the small bowel for each patient with the result of the fecal calprotectin test
Time frame: Day 30
Percentage of subjects with gastric mucosal breaks and the number of mucosal breaks
Time frame: Day 30
Change from screening visit in hemoglobin and hematocrit
Time frame: Day 30
Correlation of the number of gastric mucosal breaks with the number of small bowel mucosal breaks
Time frame: Day 30
Physical examination
Time frame: Day 30
Percentage of subjects with >=1 mucosal breaks
Time frame: Day 30
Total number of small bowel lesions with or without hemorrhage
Time frame: Day 30
Percentage of subjects with visible blood in the small bowel (without visualized lesions in the small bowel)
Time frame: Day 30
Change in Patient General Questionnaire Visual Analog Scale from Day 16
Time frame: Day 30
Change in Severity of Dyspepsia Assessment questionnaire from Day 16
Time frame: Day 30
The record gives a start of Oct 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →